Prelude Therapeutics Inc (PRLD) Gagner

Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. The company is headquartered in Wilmington, Delaware and currently employs 79 full-time employees. The company went IPO on 2020-09-25. By focusing on developing molecules using broad mechanisms that have multiple links to oncogenic driver pathways in select patients, it has developed a diverse pipeline consisting of multiple distinct programs, including kinases, targeted protein degraders, and degrader antibody conjugates. PRT12396 its lead, mutant-selective JAK2V617F inhibitor, is an open-label and multi-center study in patients with high-risk polycythemia vera and intermediate and high-risk myelofibrosis. JAK2V617F is the primary driver mutation responsible for disease progression in the majority of patients living with myeloproliferative neoplasms. The firm has discovered and is developing a series of selective and orally bioavailable KAT6A selective degraders. KAT6A is engaged in treating advanced breast cancer & other solid tumors.